(Q35564250)

8 August 2017

title

Evaluation and management of alveolitis and interstitial lung disease in scleroderma (English)

1 reference

interstitial lung disease

8 August 2017

main subject

1 reference

1 reference

https://api.crossref.org/works/10.1097/00002281-200311000-00011

23 March 2024

author name string

Panagiota I. Latsi

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14569205

23 March 2024

Athol U. Wells

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14569205

23 March 2024

language of work or name

1 reference

1 November 2003

1 reference

full work available at URL

8 August 2017

https://journals.lww.com/00002281-200311000-00011

1 reference

https://api.crossref.org/works/10.1097/00002281-200311000-00011

Current Opinion in Rheumatology

23 March 2024

published in

1 reference

8 August 2017

volume

15

1 reference

8 August 2017

issue

6

1 reference

8 August 2017

page(s)

748-755

1 reference

Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients

8 August 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1097/00002281-200311000-00011

Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival

23 March 2024

2

1 reference

https://api.crossref.org/works/10.1097/00002281-200311000-00011

Mortality and prognostic factors in Spanish patients with systemic sclerosis

23 March 2024

3

1 reference

https://api.crossref.org/works/10.1097/00002281-200311000-00011

Predictors of end stage lung disease in a cohort of patients with scleroderma

23 March 2024

4

1 reference

https://api.crossref.org/works/10.1097/00002281-200311000-00011

Predictors of end stage lung disease in systemic sclerosis

23 March 2024

5

1 reference

https://api.crossref.org/works/10.1097/00002281-200311000-00011

Pulmonary function in progressive systemic sclerosis. Comparison of CREST syndrome variant with diffuse scleroderma

23 March 2024

6

1 reference

https://api.crossref.org/works/10.1097/00002281-200311000-00011

Interstitial lung disease in progressive systemic sclerosis: high-resolution CT versus radiography

23 March 2024

7

1 reference

https://api.crossref.org/works/10.1097/00002281-200311000-00011

Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography.

23 March 2024

8

1 reference

https://api.crossref.org/works/10.1097/00002281-200311000-00011

Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement

23 March 2024

10

1 reference

https://api.crossref.org/works/10.1097/00002281-200311000-00011

Severe restrictive lung disease in systemic sclerosis.

23 March 2024

11

1 reference

https://api.crossref.org/works/10.1097/00002281-200311000-00011

Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome.

23 March 2024

12

1 reference

https://api.crossref.org/works/10.1097/00002281-200311000-00011

Structural features of interstitial lung disease in systemic sclerosis

23 March 2024

13

1 reference

https://api.crossref.org/works/10.1097/00002281-200311000-00011

Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fibrosing alveolitis.

23 March 2024

14

1 reference

https://api.crossref.org/works/10.1097/00002281-200311000-00011

American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS)

23 March 2024

15

1 reference

https://api.crossref.org/works/10.1097/00002281-200311000-00011

23 March 2024

Q28215495

16

1 reference

https://api.crossref.org/works/10.1097/00002281-200311000-00011

Non-specific interstitial pneumonia as pulmonary involvement of systemic sclerosis

23 March 2024

17

1 reference

https://api.crossref.org/works/10.1097/00002281-200311000-00011

Nonspecific interstitial pneumonia and usual interstitial pneumonia: comparative appearances at and diagnostic accuracy of thin-section CT

23 March 2024

19

1 reference

https://api.crossref.org/works/10.1097/00002281-200311000-00011

Importance of ground-glass attenuation in chronic diffuse infiltrative lung disease: pathologic-CT correlation

23 March 2024

20

1 reference

https://api.crossref.org/works/10.1097/00002281-200311000-00011

High resolution computed tomography as a predictor of lung histology in systemic sclerosis

23 March 2024

21

1 reference

https://api.crossref.org/works/10.1097/00002281-200311000-00011

Evaluation and management of scleroderma lung disease using bronchoalveolar lavage

23 March 2024

22

1 reference

https://api.crossref.org/works/10.1097/00002281-200311000-00011

Bronchoalveolar lavage for evaluation and management of scleroderma disease of the lung

23 March 2024

23

1 reference

https://api.crossref.org/works/10.1097/00002281-200311000-00011

Evaluation and management of pulmonary fibrosis in scleroderma

23 March 2024

25

1 reference

https://api.crossref.org/works/10.1097/00002281-200311000-00011

Bronchoalveolar lavage cellularity: lone cryptogenic fibrosing alveolitis compared with the fibrosing alveolitis of systemic sclerosis

23 March 2024

26

1 reference

https://api.crossref.org/works/10.1097/00002281-200311000-00011

Fibrosing alveolitis in systemic sclerosis. Bronchoalveolar lavage findings in relation to computed tomographic appearance

23 March 2024

27

1 reference

https://api.crossref.org/works/10.1097/00002281-200311000-00011

Longitudinal changes in lung function and respiratory symptoms in progressive systemic sclerosis. Prospective study

23 March 2024

28

1 reference

https://api.crossref.org/works/10.1097/00002281-200311000-00011

Interrelationships between pulmonary and extrapulmonary involvement in systemic sclerosis. A longitudinal analysis

23 March 2024

29

1 reference

https://api.crossref.org/works/10.1097/00002281-200311000-00011

Pulmonary (99m)Tc-DTPA aerosol clearance and survival in usual interstitial pneumonia (UIP)

23 March 2024

31

1 reference

https://api.crossref.org/works/10.1097/00002281-200311000-00011

Treatment of idiopathic pulmonary fibrosis: the rise and fall of corticosteroids

23 March 2024

32

1 reference

https://api.crossref.org/works/10.1097/00002281-200311000-00011

The effect of D-penicillamine on pulmonary findings in systemic sclerosis.

23 March 2024

33

1 reference

https://api.crossref.org/works/10.1097/00002281-200311000-00011

D-penicillamine therapy and interstitial lung disease in scleroderma. A long-term followup study

23 March 2024

34

1 reference

https://api.crossref.org/works/10.1097/00002281-200311000-00011

High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial

23 March 2024

35

1 reference

https://api.crossref.org/works/10.1097/00002281-200311000-00011

23 March 2024

36

20

838

Silver

1993

1 reference

https://api.crossref.org/works/10.1097/00002281-200311000-00011

Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study

23 March 2024

37

1 reference

https://api.crossref.org/works/10.1097/00002281-200311000-00011

Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide

23 March 2024

38

1 reference

https://api.crossref.org/works/10.1097/00002281-200311000-00011

Cyclophosphamide in the treatment of idiopathic pulmonary fibrosis: a prospective study in patients who failed to respond to corticosteroids

23 March 2024

39

1 reference

https://api.crossref.org/works/10.1097/00002281-200311000-00011

Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study

23 March 2024

40

1 reference

https://api.crossref.org/works/10.1097/00002281-200311000-00011

Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated with scleroderma

23 March 2024

41

1 reference

https://api.crossref.org/works/10.1097/00002281-200311000-00011

23 March 2024

42

25

1325

Varai

1998

1 reference

https://api.crossref.org/works/10.1097/00002281-200311000-00011

23 March 2024

43

29

298

Pakas

2002

1 reference

https://api.crossref.org/works/10.1097/00002281-200311000-00011

23 March 2024

44

29

731

Giacomelli

2002

1 reference

https://api.crossref.org/works/10.1097/00002281-200311000-00011

23 March 2024

45

29

2371

Griffiths

2002

1 reference

https://api.crossref.org/works/10.1097/00002281-200311000-00011

Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis.

23 March 2024

46

1 reference

https://api.crossref.org/works/10.1097/00002281-200311000-00011

Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial

23 March 2024

47

1 reference

https://api.crossref.org/works/10.1097/00002281-200311000-00011

23 March 2024

Identifiers

1 reference

8 August 2017

1 reference